Chai Zhen Hoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chai Zhen Hoo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Amy Hicks
Leeds Liver Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
1 shared publication Benedict Lim-Heng Sim
Department of Medicine, Sungai Buloh Hospital, Selangor, Malaysia
1 shared publication- Bin Gao
Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
1 shared publication Haniza Omar
Department of Hepatology and Gastroenterology, Selayang Hospital, Selangor, Malaysia
1 shared publication- Joanna Moore
Leeds Liver Unit, Leeds NHS Teaching Hospitals Trust, Leeds, UK; Leeds Institute for Medical Research, University of Leeds, Leeds, UK
1 shared publication Kar-Choon Tan
Department of Hepatology and Gastroenterology, Selayang Hospital, Selangor, Malaysia
1 shared publication
Latest Publications
- 19 May 2023
- Published by Wiley in Liver International
- Vol. 45 (3) , e15619
Novel treatment of acute and acute‐on‐chronic liver failure: Interleukin‐22
Acute liver failure (ALF) is a life‐threatening medical condition, characterized by rapidly progressive hepatic dysfunction, coagulopathy and hepatic encephalopathy in patients without chronic liver disease, while acute‐on‐chronic liver failure (ACLF) occurs in patients with existing chronic liver disease. ALF and ACLF are often associated with multiple organ failure and a high short‐term mortality. In this review, we briefly discuss the causes and pathogenesis of ALF and ACLF, the current options available for the treatment of both deadly maladies and interleukin‐22 (IL‐22), a novel promising drug that may have great therapeutic potential for ALF and ACLF treatment. IL‐22 is a cytokine produced by immune cells but mainly targets epithelial cells including hepatocytes. IL‐22 has been shown to protect against organ damage and reduce bacterial infection in many preclinical models and several clinical trials including alcohol‐associated hepatitis. The potential application of IL‐22 for the treatment of ALF and ACLF is also elaborated.
- 19 May 2023
- Published by Wiley in Liver International
- Vol. 45 (3) , e15619
Novel treatment of acute and acute‐on‐chronic liver failure: Interleukin‐22
Acute liver failure (ALF) is a life‐threatening medical condition, characterized by rapidly progressive hepatic dysfunction, coagulopathy and hepatic encephalopathy in patients without chronic liver disease, while acute‐on‐chronic liver failure (ACLF) occurs in patients with existing chronic liver disease. ALF and ACLF are often associated with multiple organ failure and a high short‐term mortality. In this review, we briefly discuss the causes and pathogenesis of ALF and ACLF, the current options available for the treatment of both deadly maladies and interleukin‐22 (IL‐22), a novel promising drug that may have great therapeutic potential for ALF and ACLF treatment. IL‐22 is a cytokine produced by immune cells but mainly targets epithelial cells including hepatocytes. IL‐22 has been shown to protect against organ damage and reduce bacterial infection in many preclinical models and several clinical trials including alcohol‐associated hepatitis. The potential application of IL‐22 for the treatment of ALF and ACLF is also elaborated.
- Open Access
- 1 April 2022
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 9 (4) , e00760
Severe Hepatocellular Liver Injury After COVID-19 Vaccination Without Autoimmune Hepatitis Features: A Case Series
Various vaccines were developed and administered to end the pandemic caused by the novel coronavirus diseases 2019 (COVID-19). These vaccines caused rare side effects not known during clinical trials. We report 2 cases of idiosyncratic drug-induced liver injury where the Pfizer BioNTech COVID-19 mRNA vaccine was administered. Both cases showed hepatocellular liver injury with negative autoimmune features on serology and histology and progressed to a protracted course of severe jaundice and pruritus before resolving without any immunosuppressants. We hope to raise awareness of possible rare side effects of the COVID-19 vaccine so that physicians can be vigilant.
- 1 April 2022
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 9 (4) , e00760
Open AccessSevere Hepatocellular Liver Injury After COVID-19 Vaccination Without Autoimmune Hepatitis Features: A Case Series
Various vaccines were developed and administered to end the pandemic caused by the novel coronavirus diseases 2019 (COVID-19). These vaccines caused rare side effects not known during clinical trials. We report 2 cases of idiosyncratic drug-induced liver injury where the Pfizer BioNTech COVID-19 mRNA vaccine was administered. Both cases showed hepatocellular liver injury with negative autoimmune features on serology and histology and progressed to a protracted course of severe jaundice and pruritus before resolving without any immunosuppressants. We hope to raise awareness of possible rare side effects of the COVID-19 vaccine so that physicians can be vigilant.